Open AccessImatinib: Time to Rethink 400 mg Starting Dose?
Author(s) -
Robert H. Carlson
Publication year - 2010
Publication title -
oncology times
Language(s) - English
Resource type - Journals
eISSN - 1548-4688
pISSN - 0276-2234
DOI - 10.1097/01.cot.0000368426.42926.06
Subject(s) - imatinib , medicine , imatinib mesylate , myeloid leukemia , chronic myelogenous leukemia , hematology , tyrosine kinase inhibitor , gastroenterology , leukemia , cancer